First-in-Class MSP (mesoporous silica particle) based therapy targets blood sugar and other metabolic risk factors.
Stockholm, Sweden, July 16, 2019 – Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies for metabolic diseases and disorders, today announces that all patients have completed treatment with SiPore15Ô in the STAR trial. Development is well on track and top-line data will be reported in October this year.
SiPore15Ô is a first-in-class medical device using specially engineered mesoporous silica particles (MSP) to achieve a reduction in blood sugar – in both prediabetics and newly diagnosed type 2 diabetics.
Sana Alajmovic, Co-Founder & CEO of Sigrid Therapeutics, states: “We are delighted to see that the collection of data in the STAR trial has progressed as planned and that we are on track for reporting results in October as already stated. No safety signals have been reported to date which continues to support the well-tolerated safety and tolerability profile we have observed in earlier clinical studies.“
Details of the 24-week STAR (Sigrid Therapeutics HbA1c Reduction), which involved 40 patients at two sites, one in Sweden, the other in Finland, can be found at www.clinicaltrials.gov/ct2/show/NCT03823027 and https://www.sigridthx.com.
